202 related articles for article (PubMed ID: 37305703)
1. Targeting PCSK9 reduces cancer cell stemness and enhances antitumor immunity in head and neck cancer.
Yang QC; Wang S; Liu YT; Song A; Wu ZZ; Wan SC; Li HM; Sun ZJ
iScience; 2023 Jun; 26(6):106916. PubMed ID: 37305703
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of PCSK9 enhances the antitumor effect of PD-1 inhibitor in colorectal cancer by promoting the infiltration of CD8
Wang R; Liu H; He P; An D; Guo X; Zhang X; Feng M
Front Immunol; 2022; 13():947756. PubMed ID: 36003387
[TBL] [Abstract][Full Text] [Related]
3. Potentiating CD8
Yuan J; Cai T; Zheng X; Ren Y; Qi J; Lu X; Chen H; Lin H; Chen Z; Liu M; He S; Chen Q; Feng S; Wu Y; Zhang Z; Ding Y; Yang W
Protein Cell; 2021 Apr; 12(4):240-260. PubMed ID: 33606190
[TBL] [Abstract][Full Text] [Related]
4. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
5. PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity.
Gu Y; Lin X; Dong Y; Wood G; Seidah NG; Werstuck G; Major P; Bonert M; Kapoor A; Tang D
J Exp Clin Cancer Res; 2023 Jan; 42(1):2. PubMed ID: 36588164
[TBL] [Abstract][Full Text] [Related]
6. Pseurotin A as a novel suppressor of hormone dependent breast cancer progression and recurrence by inhibiting PCSK9 secretion and interaction with LDL receptor.
Abdelwahed KS; Siddique AB; Mohyeldin MM; Qusa MH; Goda AA; Singh SS; Ayoub NM; King JA; Jois SD; El Sayed KA
Pharmacol Res; 2020 Aug; 158():104847. PubMed ID: 32438039
[TBL] [Abstract][Full Text] [Related]
7. PCSK9 regulates the efficacy of immune checkpoint therapy in lung cancer.
Gao X; Yi L; Jiang C; Li S; Wang X; Yang B; Li W; Che N; Wang J; Zhang H; Zhang S
Front Immunol; 2023; 14():1142428. PubMed ID: 37025995
[TBL] [Abstract][Full Text] [Related]
8. Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression.
Wang D; Yang X; Chen Y; Gong K; Yu M; Gao Y; Wu X; Hu H; Liao C; Han J; Duan Y
J Biol Chem; 2020 Nov; 295(47):15870-15882. PubMed ID: 32913121
[TBL] [Abstract][Full Text] [Related]
9. TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells.
Mao L; Xiao Y; Yang QC; Yang SC; Yang LL; Sun ZJ
Oral Oncol; 2021 Oct; 121():105472. PubMed ID: 34333450
[TBL] [Abstract][Full Text] [Related]
10. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
[TBL] [Abstract][Full Text] [Related]
11. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
[TBL] [Abstract][Full Text] [Related]
12. Tertiary Lymphoid Structure Raises Survival and Immunotherapy in HPV
Li H; Zhu SW; Zhou JJ; Chen DR; Liu J; Wu ZZ; Wang WY; Zhang MJ; Sun ZJ
J Dent Res; 2023 Jun; 102(6):678-688. PubMed ID: 36883630
[TBL] [Abstract][Full Text] [Related]
13. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A potential multifaceted player in cancer.
Bhattacharya A; Chowdhury A; Chaudhury K; Shukla PC
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188581. PubMed ID: 34144130
[TBL] [Abstract][Full Text] [Related]
14. Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9.
Le QT; Blanchet M; Seidah NG; Labonté P
J Biol Chem; 2015 Sep; 290(38):23385-400. PubMed ID: 26195630
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib attenuates reactive MDSCs enhancing anti-tumor immunity in HNSCC.
Liu J; Lin WP; Su W; Wu ZZ; Yang QC; Wang S; Sun TG; Huang CF; Wang XL; Sun ZJ
Int Immunopharmacol; 2023 Jun; 119():110243. PubMed ID: 37137265
[TBL] [Abstract][Full Text] [Related]
16. Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver.
Sun X; Essalmani R; Day R; Khatib AM; Seidah NG; Prat A
Neoplasia; 2012 Dec; 14(12):1122-31. PubMed ID: 23308045
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.
Duan Y; Chen Y; Hu W; Li X; Yang X; Zhou X; Yin Z; Kong D; Yao Z; Hajjar DP; Liu L; Liu Q; Han J
J Biol Chem; 2012 Jul; 287(28):23667-77. PubMed ID: 22593575
[TBL] [Abstract][Full Text] [Related]
18. Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism.
Guo S; Xia XD; Gu HM; Zhang DW
Adv Exp Med Biol; 2020; 1276():137-156. PubMed ID: 32705598
[TBL] [Abstract][Full Text] [Related]
19. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.
Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG
J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008
[TBL] [Abstract][Full Text] [Related]
20. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.
Ferri N; Tibolla G; Pirillo A; Cipollone F; Mezzetti A; Pacia S; Corsini A; Catapano AL
Atherosclerosis; 2012 Feb; 220(2):381-6. PubMed ID: 22176652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
